Basic Information
| LncRNA/CircRNA Name | LINC00908 |
| Synonyms | NA |
| Region | GRCh38_18:76528655-76610968 |
| Ensemble | ENSG00000263812 |
| Refseq | NR_015417 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qRT-PCR, Dual luciferase reporter assay, Western blot analysis |
| Sample | TNBC tissues,BT549 and BT474 cells,MCF7 and T47D cells,MDA-MB-468, MDA-MB-231, and 293T cells |
| Expression Pattern | down-regulated |
| Function Description | LINC00908 encoding a 60-aa polypeptide and differentially expressed in TNBC tissues.LINC00908 was directly regulated by ER?, which was responsible for the differential down-regulation of LINC00908 in TNBCs.LINC00908-encoded polypeptide ASRPS represented a TNBC-specific target for treatment. |
| Pubmed ID | 31816634 |
| Year | 2020 |
| Title | LncRNA-encoded Polypeptide ASRPS Inhibits Triple-Negative Breast Cancer Angiogenesis |
External Links
| Links for LINC00908 | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |